Repare Therapeutics is a developer of oncology drugs for patients with vulnerabilities of tumor cells. It offers a screening platform and a pipeline which provides the ability to exploit DNA Damage Repair (DDR) defects across virtually all cancers.
Repare Therapeutics is pioneering synthetic lethality to develop novel therapeutics that target specific vulnerabilities of tumors in genetically defined patient populations.
Repare was founded in 2016 by Agnel Sfeir, Daniel Durocher & Frank Sicheri. The company is based in Montreal, Quebec with an additional office in Boston, Massachusetts.
Repare’s platform combines a proprietary, high throughput, CRISPR‐enabled gene editing target discovery method with high‐resolution protein crystallography, computational biology and clinical informatics.
Repare is backed by Versant Ventures, Cowen Healthcare, OrbiMed, MPM Capital, Fonds de solidarité FTQ, BDC Healthcare Venture & Celgene among others. The company raised $82.5M in its latest funding of a "Series B" round on Sep 4, 2019. This bring Repare's total funding to $150.5M to-date.
Repare Therapeutics was named as one of 2017's Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.